Rana McKay, MD
Rana R. McKay, MD is an Associate Professor of Medicine and Urology at the University of California San Diego, Associate Director of Translational Sciences, and Co-Leader of the Genitourinary Oncology Program at the Moores Cancer Center. She is a medical oncologist who specializes in treating people with urogenital cancers. Her research interests include advanced therapeutics, precision medicine, and biomarker development. Her work has appeared in peer-reviewed publications such as The New England Journal of Medicine, Nature, Lancet, Journal of Clinical Oncology, Clinical Cancer Research, Cancer, among others. She is a member of the NCI Renal Task Force, NRG RCC Cadre Leader, and Alliance Advanced Prostate Cancer, Cadre Leader, and member of the NCCN Prostate Cancer Guidelines panel. Dr. McKay earned her medical degree at the University of Florida College of Medicine before completing her residency at Johns Hopkins Hospital. She completed a fellowship in Oncology/Hematology at the Dana-Farber Cancer Institute.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:AveoDate added:04/10/2023Date updated:04/10/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:AstraZenecaDate added:04/10/2023Date updated:04/10/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:BMSDate added:04/10/2023Date updated:04/10/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:BayerDate added:04/10/2023Date updated:04/10/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:CalitheraDate added:04/10/2023Date updated:04/10/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:CarisDate added:04/10/2023Date updated:04/10/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:DendreonDate added:04/10/2023Date updated:04/10/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:ExelixisDate added:04/10/2023Date updated:04/10/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:LillyDate added:04/10/2023Date updated:04/10/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:JNJDate added:04/10/2023Date updated:04/10/2023